Zeke Capital Advisors’s UroGen Pharma URGN Stock Holding History

Zeke Capital Advisors’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-180,000	Closed	-$1.57M	–	536
2022 Q1	$1.57M	Sell	180,000 -413,656	-70%	-$3.23M	0.08%	106
2021 Q4	$5.65M	Sell	593,656 -130,021	-18%	-$1.83M	0.33%	34
2021 Q3	$12.2M	Buy	723,677 +802	+0.1%	+$12.7K	0.7%	29
2021 Q2	$11M	Buy	722,875 +205,769	+40%	+$3.72M	0.7%	33
2021 Q1	$10.1M	Buy	+517,106	New	+$11M	0.7%	31

Other funds holding URGN

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

Stonepine Capital Management Bend, Oregon $114M AUM 77.6% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Great Point Partners Greenwich, Connecticut $408M AUM 318.81% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Millennium Management

Millennium Management New York $134B AUM 35.51% 1-Year Est. Return

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.5B AUM 68.34% 1-Year Est. Return